摘要
目的评价紫杉醇联合铂类药物对晚期非小细胞肺癌的客观疗效及毒副作用。方法经病理组织学证实的晚期非小细胞肺癌59例,采用紫杉醇135mg/m2,静脉滴注,第1天,顺铂80mg/m2,分3天给药,第2～4天,或卡铂350mg/m2。静脉滴注,第2天,21天为1个周期,2个周期以上评价疗效及毒副作用。结果全组PR24例,SD23例,PD12例,总有效率为40.7%。主要毒副作用为恶心、呕吐、骨髓抑制、关节肌肉痛等。大部分为I～1I度不良反应,患者耐受良好。结论紫杉醇联合铂类方案是1种对晚期非小细胞肺癌有效的治疗方案,毒副作用轻,值得临床进一步研究应用。
Objective To evaluate the objective eficacy and toxicity of the combination of paclitaxel with cisplatin orcarboplatin for advanced non-small cell lung cancer.Methods A total of 59 cases of advanced non-small cell lung cancer were evaluated.Paclitaxel was given at a dose of 135mg/m^2（intravenous infusion, in d1）followed by cisplatin at a dose of 80 mg/m^2（intravenous infusion,divided in 3 days which Was given from d2 to d4）or carboplatin at a dose of 350 mg/m^2 （intravenous infusion, d2）.The chemotherapy was repeated every 21 days.The eficacy and toxicity were evaluated after more than 2 cycles of thetreatment.Results Of 59 patients, 24 achieved partial response,23 had stable disease and 12 had progressive disease.Th e overall response rate was 40.7%.The major toxicities included nausea, vomiting, myelosuppression, arthralgia.and myalgia.The incidence rate of severe toxicities was generally low. These side elects were mild （garde Ⅰ-Ⅱ）and well tolerated.Conclusion The comb ination of paclitaxel with cisplatin or carboplatin is active in treating patients with advanced non-small cell lung cancer,with mild side efects, Further clinical investigation should be warranted.
出处
《医学信息》
2008年第4期508-510,共3页
Journal of Medical Information
关键词
非小细胞肺癌
紫杉醇
顺铂
Non-small cell lung cancer（NSCLC）
Paclitaxel
Cisplatin
